IL106871A - Beads having a core coated with an antifungal and a polymer - Google Patents

Beads having a core coated with an antifungal and a polymer

Info

Publication number: IL106871A
Authority: IL; Israel
Prior art keywords: percent; coating; beads; seal; polymer
Prior art date: 1992-09-03

Application number

IL106871A

Other languages

English (en)

Other versions

IL106871A0 (en

Inventor

Paul M V Gilis

Conde Valentin F V De

Roger P G Vandecruys

Original Assignee

Janssen Pharmaceutica Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-03

Filing date

1993-09-02

Publication date

1998-02-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8210890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL106871(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-09-02 Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv

1993-12-28 Publication of IL106871A0 publication Critical patent/IL106871A0/xx

1998-02-22 Publication of IL106871A publication Critical patent/IL106871A/en

Links

239000011324 bead Substances 0.000 title claims description 44
229940121375 antifungal agent Drugs 0.000 title claims description 25
230000000843 anti-fungal effect Effects 0.000 title claims description 6
229920000642 polymer Polymers 0.000 title description 5
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 33
238000000576 coating method Methods 0.000 claims description 32
239000011162 core material Substances 0.000 claims description 28
229940079593 drug Drugs 0.000 claims description 28
239000003814 drug Substances 0.000 claims description 28
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
238000005507 spraying Methods 0.000 claims description 20
239000011248 coating agent Substances 0.000 claims description 19
239000003429 antifungal agent Substances 0.000 claims description 16
229920001688 coating polymer Polymers 0.000 claims description 13
VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 12
229920001477 hydrophilic polymer Polymers 0.000 claims description 12
229960004130 itraconazole Drugs 0.000 claims description 12
238000000034 method Methods 0.000 claims description 12
HUADITLKOCMHSB-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2s,4r)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 HUADITLKOCMHSB-AVQIMAJZSA-N 0.000 claims description 11
229950005137 saperconazole Drugs 0.000 claims description 11
238000001035 drying Methods 0.000 claims description 10
239000002552 dosage form Substances 0.000 claims description 9
239000002202 Polyethylene glycol Substances 0.000 claims description 7
239000007903 gelatin capsule Substances 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
229920001223 polyethylene glycol Polymers 0.000 claims description 7
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
235000000346 sugar Nutrition 0.000 claims description 6
239000007921 spray Substances 0.000 claims description 5
229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 claims description 2
239000003960 organic solvent Substances 0.000 claims 2
239000000243 solution Substances 0.000 description 19
239000011247 coating layer Substances 0.000 description 9
229940073584 methylene chloride Drugs 0.000 description 9
239000000203 mixture Substances 0.000 description 9
239000010410 layer Substances 0.000 description 8
239000002775 capsule Substances 0.000 description 7
238000004090 dissolution Methods 0.000 description 7
239000002904 solvent Substances 0.000 description 7
239000000463 material Substances 0.000 description 5
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
238000005054 agglomeration Methods 0.000 description 4
230000002776 aggregation Effects 0.000 description 4
239000013557 residual solvent Substances 0.000 description 4
KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
230000000694 effects Effects 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
238000003756 stirring Methods 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
229920001353 Dextrin Polymers 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
229940075894 denatured ethanol Drugs 0.000 description 2
235000019425 dextrin Nutrition 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229940088679 drug related substance Drugs 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
238000001694 spray drying Methods 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical group NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
229920003148 Eudragit® E polymer Polymers 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000005913 Maltodextrin Substances 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
-1 antibacterials Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
239000000645 desinfectant Substances 0.000 description 1
238000000113 differential scanning calorimetry Methods 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000005243 fluidization Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229940098301 itraconazole 100 mg Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000009973 maize Nutrition 0.000 description 1
229940035034 maltodextrin Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
102220151657 rs763546006 Human genes 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007962 solid dispersion Substances 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
238000000935 solvent evaporation Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Processes Of Treating Macromolecular Substances (AREA)
Materials For Medical Uses (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL106871A 1992-09-03 1993-09-02 Beads having a core coated with an antifungal and a polymer IL106871A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP92202664		1992-09-03

Publications (2)

Publication Number	Publication Date
IL106871A0 IL106871A0 (en)	1993-12-28
IL106871A true IL106871A (en)	1998-02-22

Family

ID=8210890

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL106871A IL106871A (en)	1992-09-03	1993-09-02	Beads having a core coated with an antifungal and a polymer

Country Status (33)

Country	Link
US (1)	US5633015A (pl)
EP (1)	EP0658103B1 (pl)
JP (1)	JP2865869B2 (pl)
KR (1)	KR0151893B1 (pl)
CN (1)	CN1034714C (pl)
AP (1)	AP444A (pl)
AT (1)	ATE145327T1 (pl)
AU (1)	AU665867B2 (pl)
CA (1)	CA2142848C (pl)
CY (1)	CY2105B1 (pl)
CZ (1)	CZ283403B6 (pl)
DE (1)	DE69306119T2 (pl)
DK (1)	DK0658103T3 (pl)
ES (1)	ES2097536T3 (pl)
FI (1)	FI112437B (pl)
GR (1)	GR3022198T3 (pl)
HK (1)	HK1006000A1 (pl)
HR (1)	HRP931158B1 (pl)
HU (1)	HU220614B1 (pl)
IL (1)	IL106871A (pl)
MX (1)	MX9305438A (pl)
MY (1)	MY109369A (pl)
NO (1)	NO307953B1 (pl)
NZ (1)	NZ255379A (pl)
OA (1)	OA10130A (pl)
PH (1)	PH30929A (pl)
PL (2)	PL172676B1 (pl)
RU (1)	RU2125445C1 (pl)
SG (1)	SG48801A1 (pl)
SI (1)	SI9300461B (pl)
TW (1)	TW376322B (pl)
WO (1)	WO1994005263A1 (pl)
ZA (1)	ZA936493B (pl)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9325445D0 (en)	1993-12-13	1994-02-16	Cortecs Ltd	Pharmaceutical formulations
US7008668B2 (en)	1995-05-09	2006-03-07	Phoqus Pharmaceuticals Limited	Powder coating composition for electrostatic coating of pharmaceutical substrates
WO1996035516A1 (en)	1995-05-09	1996-11-14	Colorcon Limited	Electrostatic coating
US5750147A (en) *	1995-06-07	1998-05-12	Emisphere Technologies, Inc.	Method of solubilizing and encapsulating itraconazole
US6509038B2 (en) *	1996-05-20	2003-01-21	Janssen Pharmaceutica N.V.	Antifungal compositions with improved bioavailability
US5846971A (en) *	1996-06-28	1998-12-08	Schering Corporation	Oral antifungal composition
CA2258683C (en) *	1996-06-28	2007-07-31	Schering Corporation	Oral composition comprising a triazole antifungal compound
GB9623634D0 (en)	1996-11-13	1997-01-08	Bpsi Holdings Inc	Method and apparatus for the coating of substrates for pharmaceutical use
FR2758459B1 (fr) *	1997-01-17	1999-05-07	Pharma Pass	Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
CZ295502B6 (cs) *	1997-03-26	2005-08-17	Janssen Pharmaceutica N. V.	Antifungální peleta, způsob její přípravy a farmaceutická dávková forma s obsahem těchto pelet
KR19990001564A (ko) *	1997-06-16	1999-01-15	유충식	용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
PL191181B1 (pl) *	1997-12-31	2006-03-31	Choongwae Pharma Corp	Sposób wytwarzania doustnego preparatu itrakonazolu i doustny preparat itrakonazolu
KR100514330B1 (ko) *	1997-12-31	2006-02-17	주식회사 중외제약	난용성 약물을 함유하는 코팅정
DE19808634A1 (de) *	1998-02-24	1999-08-26	Schering Ag	Mantel für eine pharmazeutische Zusammensetzung
UA65607C2 (uk)	1998-03-04	2004-04-15	Орто-Макнейл Фармацевтикал, Інк.	Фармацевтична композиція (варіанти) та спосіб її приготування
DK1104291T3 (da)	1998-07-17	2006-01-16	Janssen Pharmaceutica Nv	Pelleter med en kerne, som er coatet med et antisvampemiddel og en polymer
ES2157731B1 (es) *	1998-07-21	2002-05-01	Liconsa Liberacion Controlada	Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DK1163234T3 (da)	1999-03-24	2006-02-27	Scherer Technologies Inc R P	Farmaceutiske formuleringer med forbedret vandoplöselighed
KR100331529B1 (ko) *	1999-06-16	2002-04-06	민경윤	난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
US20030236236A1 (en) *	1999-06-30	2003-12-25	Feng-Jing Chen	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20030180352A1 (en) *	1999-11-23	2003-09-25	Patel Mahesh V.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20060034937A1 (en) *	1999-11-23	2006-02-16	Mahesh Patel	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
KR100694667B1 (ko) *	1999-12-08	2007-03-14	동아제약주식회사	생체내이용률 향상과 개인간 및 개인내 흡수 편차를감소시킨 이트라코나졸 함유 항진균성 제제
JP5159012B2 (ja) *	1999-12-23	2013-03-06	メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド	不良溶解性の薬物に対する改良された医薬組成物
GB0002305D0 (en)	2000-02-01	2000-03-22	Phoqus Limited	Power material for electrostatic application
CN102772413A (zh) *	2000-02-29	2012-11-14	布里斯托尔-迈尔斯斯奎布公司	低剂量艾替开韦制剂及其应用
US6551608B2 (en) *	2000-03-06	2003-04-22	Porex Technologies Corporation	Porous plastic media with antiviral or antimicrobial properties and processes for making the same
US6977085B2 (en) *	2000-12-22	2005-12-20	Baxter International Inc.	Method for preparing submicron suspensions with polymorph control
US6673373B2 (en)	2001-02-01	2004-01-06	Carlsbad Technology Inc.	Antifungal formulation and the methods for manufacturing and using the same
US6663897B2 (en) *	2001-02-06	2003-12-16	Dsm Ip Assets B.V.	Oral itraconazole formulations and methods of making the same
EP1370543B1 (en)	2001-02-14	2006-10-25	Tibotec Pharmaceuticals Ltd.	Broadspectrum 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors
EP1397367A2 (en)	2001-04-09	2004-03-17	Tibotec Pharmaceuticals Ltd.	Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
US7622490B2 (en)	2001-05-11	2009-11-24	Tibotec Pharmaceuticals, Ltd.	Broadspecturm 2-amino-benzoxazole sulfonamide HIV protease inhibitors
US20030070584A1 (en) *	2001-05-15	2003-04-17	Cynthia Gulian	Dip coating compositions containing cellulose ethers
AU4061702A (en) *	2001-05-15	2003-04-03	Mcneil-Ppc, Inc.	Dip coating compositions containing starch or dextrin
KR100438485B1 (ko) *	2001-08-13	2004-07-09	한국디디에스제약 주식회사	아졸류 항진균제의 약제학적 조성물
US8071133B2 (en)	2001-08-20	2011-12-06	Stiefel Laboratories, Inc.	Oral dosage forms of water insoluble drugs and methods of making the same
US8309118B2 (en) *	2001-09-28	2012-11-13	Mcneil-Ppc, Inc.	Film forming compositions containing sucralose
CA2363376A1 (en) *	2001-11-16	2003-05-16	Bernard Charles Sherman	Solid pharmaceutical compositions for oral administration comprising itraconazole
US7763641B2 (en)	2001-12-21	2010-07-27	Tibotec Pharmaceuticals Ltd.	Broadspectrum heterocyclic substituted phenyl containing sulfonamide HIV protease inhibitors
EP1469830A2 (en) *	2002-02-01	2004-10-27	Pfizer Products Inc.	Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
US20100311701A1 (en) *	2002-02-15	2010-12-09	Transform Pharmaceuticals, Inc	Pharmaceutical Co-Crystal Compositions
US7927613B2 (en)	2002-02-15	2011-04-19	University Of South Florida	Pharmaceutical co-crystal compositions
US7446107B2 (en) *	2002-02-15	2008-11-04	Transform Pharmaceuticals, Inc.	Crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) *	2002-02-15	2010-09-07	Mcneil-Ppc, Inc.	Pharmaceutical propylene glycol solvate compositions
IL163846A0 (en) *	2002-03-01	2005-12-18	Univ South Florida	Multiple-component solid phases containing at least one active pharmaceutical ingredient
MY142238A (en)	2002-03-12	2010-11-15	Tibotec Pharm Ltd	Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
CA2485903C (en)	2002-05-17	2011-08-16	Tibotec Pharmaceuticals Ltd.	Broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
EP1511490A4 (en) *	2002-05-31	2009-03-11	Transform Pharmaceuticals Inc	NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS
US20070059356A1 (en) *	2002-05-31	2007-03-15	Almarsson Oern	Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
IL165383A0 (en) *	2002-06-21	2006-01-15	Transform Pharmaceuticals Inc	Pharmaceutical compositions with improved dissolution
EP1542728A4 (en) *	2002-07-22	2005-09-21	Nanohybrid Co Ltd	HYBRID OF ITRACONAZOLE, CYCLOSPORINE OR CARVEDILOL WITH A LAYERED SILICATE AND PROCESS FOR PREPARING THE SAME
US7429619B2 (en) *	2002-08-02	2008-09-30	Mcneil Consumer Healthcare	Polyacrylic film forming compositions
NZ538714A (en)	2002-08-14	2007-03-30	Tibotec Pharm Ltd	Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors
WO2007014130A2 (en) *	2005-07-21	2007-02-01	Nomir Medical Technologies, Inc.	Near infrared microbial elimination laser system (nimels)
US20040086567A1 (en) *	2002-10-30	2004-05-06	Pawan Seth	Bioequivalent composition of itraconazole and a hydrophilic polymer
ATE544354T1 (de)	2002-11-26	2012-02-15	Univ Chicago	Vermeidung und behandlung von mikrobenübertragenen epithelerkrankungen
US8183290B2 (en) *	2002-12-30	2012-05-22	Mcneil-Ppc, Inc.	Pharmaceutically acceptable propylene glycol solvate of naproxen
DK1438961T4 (da) †	2003-01-14	2014-11-17	Acino Pharma Ag	Bioækvivalent sammensætning af itraconazol dispergeret i en hydrofil polymer
DK1438960T4 (da) *	2003-01-14	2013-03-25	Cimex Pharma Ag	Sammensætning af itraconazol dispergeret i en hydrofil polymer med forhøjet biotilgængelighed
FR2852607B1 (fr) *	2003-03-20	2006-07-14		Procede de fabrication de microspheres de sucre de petite taille, les microspheres susceptibles d'etre obtenues par ce procede et leurs applications
CA2531766C (en)	2003-09-11	2012-11-27	Tibotec Pharmaceuticals Ltd.	Entry inhibitors of the hiv virus
US20050074494A1 (en) *	2003-10-06	2005-04-07	Xiu-Xiu Cheng	Itraconazole immediate release formulation
US20050118265A1 (en) *	2003-11-28	2005-06-02	Anandi Krishnan	Antifungal oral dosage forms and the methods for preparation
US9247765B2 (en)	2004-01-14	2016-02-02	Omniactive Health Technologies Limited	Stable beadlets of lipophilic nutrients
US20050249799A1 (en) *	2004-03-03	2005-11-10	Spherics, Inc.	Polymeric drug delivery system for hydrophobic drugs
GB0407312D0 (en)	2004-03-31	2004-05-05	Phoqus Pharmaceuticals Ltd	Method and apparatus for the application of powder material to substrates
AR048650A1 (es)	2004-05-04	2006-05-10	Tibotec Pharm Ltd	Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
AU2005244121B2 (en)	2004-05-07	2012-01-19	Sequoia Pharmaceuticals, Inc.	Resistance-repellent retroviral protease inhibitors
MXPA06013315A (es)	2004-05-17	2007-02-02	Tibotec Pharm Ltd	1,5-dihidro-pirido[3,2-b]indol-2-onas 4-sustituidas.
TW200607502A (en)	2004-05-17	2006-03-01	Tibotec Pharm Ltd	6, 7, 8, 9-substituted 1-phenyl-1, 5-dihydro-pyrido[3, 2-b]indol-2-ones
KR20070015608A (ko)	2004-05-17	2007-02-05	티보텍 파마슈티칼즈 리미티드	1-헤테로사이클일-1,5-디히드로-피리도[3,2-ｂ]인돌-2-온
US20070281007A1 (en) *	2004-08-27	2007-12-06	Jacob Jules S	Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
US20060045865A1 (en) *	2004-08-27	2006-03-02	Spherics, Inc.	Controlled regional oral delivery
US20060045822A1 (en) *	2004-09-01	2006-03-02	Board Of Regents, The University Of Texas System	Plasma polymerization for encapsulating particles
US20100297251A1 (en) *	2004-09-01	2010-11-25	Board Of Regents, The University Of Texas System	Encapsulated particles for enteric release
FR2883179B1 (fr)	2005-03-18	2009-04-17	Ethypharm Sa	Comprime enrobe
AR056652A1 (es)	2005-04-11	2007-10-17	Tibotec Pharm Ltd	Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
US20070148240A1 (en) *	2005-12-23	2007-06-28	Fang-Yu Lee	Oral formulation containing itraconazole and methods for manufacturing and using the same
RU2008143342A (ru)	2006-04-03	2010-05-10	Тиботек Фармасьютикалз Лтд. (Ie)	3, 4-дигидроимидазо(4, 5-b)пиридин-5-оны, ингибирующие вич(hiv)
CN101091725A (zh) *	2006-06-23	2007-12-26	天津天士力制药股份有限公司	一种中药颗粒及其制备方法
EP2134327A1 (en) *	2007-03-13	2009-12-23	Sandoz AG	Pharmaceutical compositions of poorly soluble drugs
CN101283984B (zh) *	2007-04-12	2010-05-26	永胜药品工业股份有限公司	高生物使用率的经杀真菌剂和聚合物涂覆的核心微粒状物
US7314641B1 (en)	2007-04-18	2008-01-01	Everest Pharm. Industrial Co., Ltd.	High-bioavailability particle coated with fungicide and polymer
JP2008280254A (ja) *	2007-05-08	2008-11-20	Everest Pharm Industrial Co Ltd	生体に使用される比率が高い、殺菌剤と重合物を塗粧してる核心微粒状物
JP5745855B2 (ja)	2007-11-28	2015-07-08	セコイア、ファーマシューティカルズ、インコーポレイテッドＳｅｑｕｏｉａＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	シトクロムｐ４５０２ｄ６を阻害するための組成物および方法
CA2716348C (en)	2008-02-21	2017-04-04	Sequoia Pharmaceuticals, Inc.	Diamide inhibitors of cytochrome p450
WO2009114834A2 (en)	2008-03-13	2009-09-17	Board Of Regents, The University Of Texas System	Covalently functionalized particles for synthesis of new composite materials
US11304960B2 (en) *	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
GB2479213B (en)	2010-04-01	2013-07-10	Theravida Inc	Pharmaceutical formulations for the treatment of overactive bladder
WO2011146077A1 (en) *	2010-05-21	2011-11-24	Board Of Regents, The University Of Texas System	Encapsulated particles for amorphous stability enhancement
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
CN103402543B (zh) *	2010-12-16	2015-09-16	德克萨斯州立大学董事会	用于胃肠外施用的吡咯药物制剂及其制备方法和治疗对吡咯化合物敏感的疾病的使用方法
EP2706997B1 (en)	2011-05-10	2019-03-27	TheraVida, Inc.	Combinations of solifenacin and pilocarpine for the treatment of overactive bladder
JP2015531749A (ja)	2012-06-21	2015-11-05	メインファーマインターナショナルプロプライエタリーリミテッドＭａｙｎｅＰｈａｒｍａＩｎｔｅｒｎａｔｉｏｎａｌＰｔｙ．Ｌｔｄ．	イトラコナゾール組成物及び投与剤形、並びにその使用方法
CN103948911B (zh) *	2014-04-23	2016-04-20	深圳市健元医药科技有限公司	一种棘白菌素类抗真菌药物缓释微球制剂及其制备方法
WO2016033549A2 (en)	2014-08-28	2016-03-03	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en)	2014-08-28	2016-11-22	Lipocine Inc.	Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016205423A2 (en)	2015-06-15	2016-12-22	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
KR102600541B1 (ko)	2016-01-20	2023-11-08	테라비다, 인코포레이티드	다한증을 치료하기 위한 방법 및 조성물
CA3078723A1 (en)	2016-11-28	2018-05-31	Nachiappan Chidambaram	Oral testosterone undecanoate therapy
EP3824296B1 (en)	2018-07-20	2026-04-01	Lipocine Inc.	Oral pharmaceutical composition comprising testosterone tridecanoate and/or testosterone dodecanoate for treating liver diseases
CN118695852A (zh) *	2021-12-22	2024-09-24	帕劳制药有限公司	多颗粒阿巴康唑组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2514261B1 (fr) *	1981-10-08	1986-08-22	Aec Chim Organ Biolog	Nouvelle composition pour l'enrobage des aliments et des medicaments et granules ainsi enrobes
FR2556964A1 (fr) *	1983-12-23	1985-06-28	Ile De France	Nouvelles formes galeniques du sulpiride utilisables par voie orale
NZ223799A (en) *	1987-03-25	1989-12-21	Janssen Pharmaceutica Nv	Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions
US4916134A (en) *	1987-03-25	1990-04-10	Janssen Pharmacuetica N.V.	4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
US4855326A (en) *	1987-04-20	1989-08-08	Fuisz Pharmaceutical Ltd.	Rapidly dissoluble medicinal dosage unit and method of manufacture
JPH01165520A (ja) *	1987-12-23	1989-06-29	Shin Etsu Chem Co Ltd	持続性製剤およびその製造方法
US5049374A (en) *	1989-11-28	1991-09-17	Dansereau Richard J	Oral (coated bead) dosage form for sodium iodide I-131
US5213811A (en) *	1991-09-13	1993-05-25	Sterling Drug Inc.	Oral sustained-release drug compositions

1993
- 1993-08-13 PH PH46686A patent/PH30929A/en unknown
- 1993-08-26 TW TW082106900A patent/TW376322B/zh not_active IP Right Cessation
- 1993-08-27 AU AU49546/93A patent/AU665867B2/en not_active Expired
- 1993-08-27 EP EP93919206A patent/EP0658103B1/en not_active Expired - Lifetime
- 1993-08-27 AT AT93919206T patent/ATE145327T1/de active
- 1993-08-27 DK DK93919206.8T patent/DK0658103T3/da active
- 1993-08-27 HK HK98105166A patent/HK1006000A1/en not_active IP Right Cessation
- 1993-08-27 NZ NZ255379A patent/NZ255379A/en not_active IP Right Cessation
- 1993-08-27 PL PL93307791A patent/PL172676B1/pl unknown
- 1993-08-27 CA CA002142848A patent/CA2142848C/en not_active Expired - Lifetime
- 1993-08-27 ES ES93919206T patent/ES2097536T3/es not_active Expired - Lifetime
- 1993-08-27 SG SG1996001839A patent/SG48801A1/en unknown
- 1993-08-27 RU RU95108537A patent/RU2125445C1/ru active
- 1993-08-27 DE DE69306119T patent/DE69306119T2/de not_active Expired - Lifetime
- 1993-08-27 KR KR1019950700756A patent/KR0151893B1/ko not_active Expired - Lifetime
- 1993-08-27 CZ CZ95542A patent/CZ283403B6/cs not_active IP Right Cessation
- 1993-08-27 PL PL93318659A patent/PL174178B1/pl unknown
- 1993-08-27 US US08/432,188 patent/US5633015A/en not_active Expired - Lifetime
- 1993-08-27 WO PCT/EP1993/002327 patent/WO1994005263A1/en not_active Ceased
- 1993-08-27 JP JP6506851A patent/JP2865869B2/ja not_active Expired - Lifetime
- 1993-08-27 HU HU9500642A patent/HU220614B1/hu unknown
- 1993-09-01 MY MYPI93001754A patent/MY109369A/en unknown
- 1993-09-02 IL IL106871A patent/IL106871A/en not_active IP Right Cessation
- 1993-09-02 HR HR92202664.6A patent/HRP931158B1/xx not_active IP Right Cessation
- 1993-09-02 CN CN93117313A patent/CN1034714C/zh not_active Expired - Lifetime
- 1993-09-02 AP APAP/P/1993/000563A patent/AP444A/en active
- 1993-09-02 ZA ZA936493A patent/ZA936493B/xx unknown
- 1993-09-03 MX MX9305438A patent/MX9305438A/es unknown
- 1993-09-03 SI SI9300461A patent/SI9300461B/sl unknown
1995
- 1995-03-01 OA OA60618A patent/OA10130A/en unknown
- 1995-03-02 NO NO950829A patent/NO307953B1/no not_active IP Right Cessation
- 1995-03-02 FI FI950975A patent/FI112437B/fi not_active IP Right Cessation
1996
- 1996-12-31 GR GR960403258T patent/GR3022198T3/el unknown
1998
- 1998-06-16 CY CY9800007A patent/CY2105B1/xx unknown

Also Published As

Publication number	Publication date
AP444A (en)	1996-01-19
CA2142848A1 (en)	1994-03-17
NO307953B1 (no)	2000-06-26
HU220614B1 (hu)	2002-03-28
FI950975L (fi)	1995-03-02
AU665867B2 (en)	1996-01-18
HUT70419A (en)	1995-10-30
OA10130A (en)	1996-12-18
CA2142848C (en)	1999-11-16
AU4954693A (en)	1994-03-29
JP2865869B2 (ja)	1999-03-08
FI950975A0 (fi)	1995-03-02
HU9500642D0 (en)	1995-04-28
NZ255379A (en)	1996-06-25
EP0658103B1 (en)	1996-11-20
FI112437B (fi)	2003-12-15
RU2125445C1 (ru)	1999-01-27
PL307791A1 (en)	1995-06-26
SG48801A1 (en)	1998-05-18
ATE145327T1 (de)	1996-12-15
CN1034714C (zh)	1997-04-30
IL106871A0 (en)	1993-12-28
CY2105B1 (en)	2002-04-26
JPH08501092A (ja)	1996-02-06
PH30929A (en)	1997-12-23
PL172676B1 (pl)	1997-11-28
MY109369A (en)	1997-01-31
NO950829D0 (no)	1995-03-02
HRP931158A2 (en)	1995-06-30
AP9300563A0 (en)	1993-10-31
CZ54295A3 (en)	1995-09-13
US5633015A (en)	1997-05-27
ZA936493B (en)	1995-03-02
TW376322B (en)	1999-12-11
SI9300461A (en)	1994-03-31
KR0151893B1 (ko)	1998-10-15
EP0658103A1 (en)	1995-06-21
CN1088432A (zh)	1994-06-29
DE69306119D1 (de)	1997-01-02
GR3022198T3 (en)	1997-03-31
NO950829L (no)	1995-05-02
PL174178B1 (pl)	1998-06-30
SI9300461B (en)	2001-12-31
DE69306119T2 (de)	1997-03-13
HRP931158B1 (en)	1999-02-28
DK0658103T3 (da)	1996-12-09
ES2097536T3 (es)	1997-04-01
MX9305438A (es)	1994-03-31
CZ283403B6 (cs)	1998-04-15
HK1006000A1 (en)	1999-02-05
WO1994005263A1 (en)	1994-03-17

Legal Events

Date	Code	Title
1998-08-16	FF	Patent granted
1998-12-06	KB	Patent renewed
2000-01-31	KB	Patent renewed
2003-11-23	KB	Patent renewed
2007-10-31	KB	Patent renewed
2011-09-27	KB	Patent renewed
2014-04-30	EXP	Patent expired

Publication	Publication Date	Title
US5633015A (en)	1997-05-27	Beads having a core coated with an antifungal and a polymer
HK1006000B (en)	1999-02-05	Beads having a core coated with an antifungal and a polymer
CA2269501C (en)	2005-11-08	Pellets having a core coated with an antifungal and a polymer
CA2315110C (en)	2006-09-12	Pellets having a core coated with an antifungal and a polymer
WO1999055313A1 (en)	1999-11-04	Pellets having a core coated with a lipid lowering agent and a polymer
MXPA99004411A (en)	1999-09-01	Pellets having a core coated with an antifungal and a polymer
HK1022840B (en)	2003-09-05	Pellets having a core coated with an antifungal and a polymer